CAMBRIDGE, Mass. & BRISBANE, Australia (BUSINESS WIRE) Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer. Doug joins Vaxxas as the company.
Australian biotech giant Ellume Limited has gone into voluntary administration. It comes after the company dealt with a number of false-positives and stock recalls for their Covid tests.